SlideShare a Scribd company logo
Reference PMID: 28146134
INTRODUCTION
 Next-generation sequencing (NGS) technology has expanded in the
last decades with enhancement in the reliability, sequencing
chemistry, pipeline analyses, data interpretation and costs.
 Such advances make the use of NGS feasible in clinical practice .
This review describes the recent technological developments in
NGS applied to the field of oncology.
 Next-generation sequencing (NGS) is also called massive parallel
sequencing
 Some advantages of NGS sequencers are the high-throughput
sequencing capacity of large genomic regions or small regions for
many samples.
 Nowadays, the use of NGS almost replaced conventional Sanger
sequencing and is a very versatile approach for several clinical and
non-clinical applications.
 It is very cost effective
Next generation sequencing
AIM
 The present review describes the major factor in NGS technology, the technical
developments and application of NGS to the field of oncology, i.e., hereditary
cancer syndromes and sporadic cancer and it’s diagnostics
 NGS studies exploring the somatic mutation profile in cancer .
 In clinical diagnostics, in order to identify familial germline mutations, WGS may
be useful in case genetic tests based on WES returned a negative result in families
with a high probability of carrying a genetic mutation.
 A thorough overview of the different NGS platforms and approaches e.g. Illumina
 Current NGS technology is sorted in two major types, i.e., short- and long-read
sequencing
 Short-read sequencing has low costs per Gb and high accuracy (low final error-rate;
0.1 Kb) and has been the method most frequently used .
 In contrast, the low accuracy (high final error-rate; >1 Kb) and the high costs per
Gb of long-read sequencing make the use of these approaches non-versatile for all-
purposes
PROCEDURE
 The initial input material can be genomic DNA (DNA-seq),
messenger or non-coding RNA (RNA-seq) or any
nucleic/ribonucleic material obtained after specific procedures.
 The implementation of NGS technology can be visualised as four
major blocks:-
1) Library preparation
2) Sequencing
3) Quality analysis
4) Data Analysis interpretation
Next generation sequencing
DATA ANYLYSIS
 After raw data are assessed for sufficient quality,
data analyses and interpretation continues using
different pipelines depending on the approach used
(gene-panel, WES, WGS or targeted-RNA-seq)
 It was indicated that genes
besides BRCA1 and BRCA2 are mutated and confer
a moderate to high cancer risk
 Aloraifi and co-workers [1] sequenced 312 genes
among 104 BRCAx subjects and found that 13
subjects carried a pathogenic variant, most
frequently occurring
in ATM, RAD50, PALB2, CHEK2 and TP53
Next generation sequencing
CONCLUSION
 In conclusions, liquid biopsy analyses by NGS have been applied to
several cancer types like hepatocellular carcinoma [278],
gynaecological cancer [2], lung cancer [3,5], urinary tract cancer
[271], paediatric oncology [6], gastrointestinal tumours [7] and
other types, even through WES/WGS analyses [8,9]
 The NGS approach for PGx can involve the analysis of the entire
exome (WES) or the entire genome (WGS). WGS has the main
advantage of encompassing also the non-coding regions, e.g.,
involved in regulation of transcription or affecting splicing, which is
not present in WES data
 NGS has brought unprecedented advances in understanding the
biology of diseases, with important clinical implications .
REFERENCE
1. Aloraifi F., McDevitt T., Martiniano R., McGreevy J., McLaughlin R., Egan C.M.,
Cody N., Meany M., Kenny E., Green A.J., et al. Detection of novel germline
mutations for breast cancer in non-BRCA1/2families. FEBS J. 2015;282:3424–3437.
doi: 10.1111/febs.13352. [PubMed] [Cross Ref]
2. Forshew T., Murtaza M., Parkinson C., Gale D., Tsui D.W., Kaper F., Dawson S.J.,
Piskorz A.M., Jimenez-Linan M., Bentley D., et al. Noninvasive identification and
monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci.
Transl. Med. 2012;4:136ra68. doi: 10.1126/scitranslmed.3003726. [PubMed] [Cross
Ref]
3. Couraud S., Vaca-Paniagua F., Villar S., Oliver J., Schuster T., Blanche H., Girard N.,
Tredaniel J., Guilleminault L., Gervais R., et al. Noninvasive diagnosis of actionable
mutations by deep sequencing of circulating free DNA in lung cancer from never-
smokers: A proof-of-concept study from BioCAST/IFCT-1002. Clin. Cancer
Res. 2014;20:4613–4624. doi: 10.1158/1078-0432.CCR-13-3063. [PubMed][Cross
Ref]
4. Ward D.G., Baxter L., Gordon N.S., Ott S., Savage R.S., Beggs A.D., James J.D.,
Lickiss J., Green S., Wallis Y., et al. Multiplex PCR and Next Generation Sequencing
for the Non-Invasive Detection of Bladder Cancer. PLoS ONE. 2016;11:e0149756
doi: 10.1371/journal.pone.0149756. [PMC free article][PubMed] [Cross Ref]
5. Xu S., Lou F., Wu Y., Sun D.Q., Zhang J.B., Chen W., Ye H., Liu J.H., Wei S., Zhao M.Y., et
al. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell
lung cancer patients. Cancer Lett. 2016;370:324–331. doi:
10.1016/j.canlet.2015.11.005. [PubMed] [Cross Ref]
6. Kurihara S., Ueda Y., Onitake Y., Sueda T., Ohta E., Morihara N., Hirano S., Irisuna F.,
Hiyama E. Circulating free DNA as non-invasive diagnostic biomarker for childhood solid
tumors. J. Pediatr. Surg. 2015;50:2094–2097. doi:
10.1016/j.jpedsurg.2015.08.033. [PubMed] [Cross Ref]
7. Ueda M., Iguchi T., Masuda T., Nakahara Y., Hirata H., Uchi R., Niida A., Momose K.,
Sakimura S., Chiba K., et al. Somatic mutations in plasma cell-free DNA are diagnostic
markers for esophageal squamous cell carcinoma recurrence. Oncotarget. 2016;7:62280–
62291. doi: 10.18632/oncotarget.11409.[PMC free article] [PubMed] [Cross Ref]
8. Gasch C., Pantel K., Riethdorf S. Whole Genome Amplification in Genomic Analysis of
Single Circulating Tumor Cells. Methods Mol. Biol. 2015;1347:221–232. [PubMed]
9. Huang L., Ma F., Chapman A., Lu S., Xie X.S. Single-Cell Whole-Genome Amplification
and Sequencing: Methodology and Applications. Annu. Rev. Genom. Hum. Genet. 2015;16:79–
102. doi: 10.1146/annurev-genom-090413-025352. [PubMed] [Cross Ref]
Next generation sequencing

More Related Content

PDF
Genomics: Personalised Medicine in Brain Cancer?
PDF
Ong et al._Translational utility of next-generation sequencing_2013_Genomics
PDF
ACC Cancer Cell May 2016
DOCX
Annotated Bibliography
PPTX
CSF-Derived cell-free DNA for Diagnosis and Characterization of.pptx
PPTX
Next Generation Sequencing
PDF
Methods, Challenges and Future Directions of Radiogenomics-Crimson Publishers
PPT
Colon Cancer PDX Organoids and Cell Lines
Genomics: Personalised Medicine in Brain Cancer?
Ong et al._Translational utility of next-generation sequencing_2013_Genomics
ACC Cancer Cell May 2016
Annotated Bibliography
CSF-Derived cell-free DNA for Diagnosis and Characterization of.pptx
Next Generation Sequencing
Methods, Challenges and Future Directions of Radiogenomics-Crimson Publishers
Colon Cancer PDX Organoids and Cell Lines

What's hot (20)

PDF
REFRACT Lima 2019
PPT
Biology m(1)
PPTX
Bioinformatics in pandemic
PDF
2016-Crawford-BMC Pulm Med published
PDF
s12935-014-0115-7
PPTX
NGS in cancer treatment
PDF
genomics upenn publication 1
PDF
Medical genetics
PPT
Folding: NEWS Principles of Medical Genetics
PDF
Gb 2011-12-9-228
DOCX
Genetic Mapping & its applications in different field of science
PDF
TCGC The Clinical Genome Conference 2015
PPTX
Ebs schwannomatosis
PPTX
petros tsipouras
PDF
Ren s cv@2016
PDF
Camryn Romph Senior Thesis
PPT
Principles of Medical Genetics
PDF
Resume_Das
PPTX
Vemurafenib in multiple nonmelanoma cancers with braf v600 shubhda roy
PDF
Low expression of N-myc downstream-regulated gene 2 in oesophageal squamous c...
REFRACT Lima 2019
Biology m(1)
Bioinformatics in pandemic
2016-Crawford-BMC Pulm Med published
s12935-014-0115-7
NGS in cancer treatment
genomics upenn publication 1
Medical genetics
Folding: NEWS Principles of Medical Genetics
Gb 2011-12-9-228
Genetic Mapping & its applications in different field of science
TCGC The Clinical Genome Conference 2015
Ebs schwannomatosis
petros tsipouras
Ren s cv@2016
Camryn Romph Senior Thesis
Principles of Medical Genetics
Resume_Das
Vemurafenib in multiple nonmelanoma cancers with braf v600 shubhda roy
Low expression of N-myc downstream-regulated gene 2 in oesophageal squamous c...
Ad

Similar to Next generation sequencing (20)

PPTX
APPLICATION OF NEXT GENERATION SEQUENCING (NGS) IN CANCER TREATMENT
PDF
NGS application in Kuwait cancer control center
PPTX
Next generation Sequencing in Drug Discovery
PPTX
Applications of Next generation sequencing in Drug Discovery
PPTX
Next Generation Sequencing
PPT
20160219 - S. De Toffol - Dal Sanger al NGS nello studio delle mutazioni BRCA
PPTX
Chapter 2.4 tmb and ngs
PPTX
GTC group 8 - Next Generation Sequencing
PDF
Translating next generation sequencing to practice
PDF
Next-Generation Sequencing an Intro to Tech and Applications: NGS Tech Overvi...
PDF
Goodwin2016 ngs 10 years
PDF
Genes and Tissue Culture Technology - Next Generation Sequencing - Applicatio...
PDF
Advanced NGS Data Analysis & Interpretation- BGW + IVA: NGS Tech Overview Web...
PDF
Ngs part i 2013
PPTX
Clinical Applications of Next Generation Sequencing
PDF
Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...
PDF
The quest for high confidence mutations in plasma: searching for a needle in ...
PDF
Chapter 1 cancer genome
PPTX
Cancer genome (2)
PDF
fonc-04-00078.pdf
APPLICATION OF NEXT GENERATION SEQUENCING (NGS) IN CANCER TREATMENT
NGS application in Kuwait cancer control center
Next generation Sequencing in Drug Discovery
Applications of Next generation sequencing in Drug Discovery
Next Generation Sequencing
20160219 - S. De Toffol - Dal Sanger al NGS nello studio delle mutazioni BRCA
Chapter 2.4 tmb and ngs
GTC group 8 - Next Generation Sequencing
Translating next generation sequencing to practice
Next-Generation Sequencing an Intro to Tech and Applications: NGS Tech Overvi...
Goodwin2016 ngs 10 years
Genes and Tissue Culture Technology - Next Generation Sequencing - Applicatio...
Advanced NGS Data Analysis & Interpretation- BGW + IVA: NGS Tech Overview Web...
Ngs part i 2013
Clinical Applications of Next Generation Sequencing
Utilization of NGS to Identify Clinically-Relevant Mutations in cfDNA: Meet t...
The quest for high confidence mutations in plasma: searching for a needle in ...
Chapter 1 cancer genome
Cancer genome (2)
fonc-04-00078.pdf
Ad

Recently uploaded (20)

PDF
Looking into the jet cone of the neutrino-associated very high-energy blazar ...
PPT
veterinary parasitology ````````````.ppt
PPTX
TOTAL hIP ARTHROPLASTY Presentation.pptx
PPT
1. INTRODUCTION TO EPIDEMIOLOGY.pptx for community medicine
PPTX
BODY FLUIDS AND CIRCULATION class 11 .pptx
PPTX
Microbes in human welfare class 12 .pptx
PDF
CAPERS-LRD-z9:AGas-enshroudedLittleRedDotHostingaBroad-lineActive GalacticNuc...
PPTX
Fluid dynamics vivavoce presentation of prakash
PDF
. Radiology Case Scenariosssssssssssssss
PDF
The scientific heritage No 166 (166) (2025)
PDF
Lymphatic System MCQs & Practice Quiz – Functions, Organs, Nodes, Ducts
PPT
Heredity-grade-9 Heredity-grade-9. Heredity-grade-9.
PDF
Is Earendel a Star Cluster?: Metal-poor Globular Cluster Progenitors at z ∼ 6
PDF
Unveiling a 36 billion solar mass black hole at the centre of the Cosmic Hors...
PPTX
POULTRY PRODUCTION AND MANAGEMENTNNN.pptx
PPTX
Hypertension_Training_materials_English_2024[1] (1).pptx
PDF
Formation of Supersonic Turbulence in the Primordial Star-forming Cloud
PPTX
Biomechanics of the Hip - Basic Science.pptx
PPTX
BIOMOLECULES PPT........................
DOCX
Q1_LE_Mathematics 8_Lesson 5_Week 5.docx
Looking into the jet cone of the neutrino-associated very high-energy blazar ...
veterinary parasitology ````````````.ppt
TOTAL hIP ARTHROPLASTY Presentation.pptx
1. INTRODUCTION TO EPIDEMIOLOGY.pptx for community medicine
BODY FLUIDS AND CIRCULATION class 11 .pptx
Microbes in human welfare class 12 .pptx
CAPERS-LRD-z9:AGas-enshroudedLittleRedDotHostingaBroad-lineActive GalacticNuc...
Fluid dynamics vivavoce presentation of prakash
. Radiology Case Scenariosssssssssssssss
The scientific heritage No 166 (166) (2025)
Lymphatic System MCQs & Practice Quiz – Functions, Organs, Nodes, Ducts
Heredity-grade-9 Heredity-grade-9. Heredity-grade-9.
Is Earendel a Star Cluster?: Metal-poor Globular Cluster Progenitors at z ∼ 6
Unveiling a 36 billion solar mass black hole at the centre of the Cosmic Hors...
POULTRY PRODUCTION AND MANAGEMENTNNN.pptx
Hypertension_Training_materials_English_2024[1] (1).pptx
Formation of Supersonic Turbulence in the Primordial Star-forming Cloud
Biomechanics of the Hip - Basic Science.pptx
BIOMOLECULES PPT........................
Q1_LE_Mathematics 8_Lesson 5_Week 5.docx

Next generation sequencing

  • 2. INTRODUCTION  Next-generation sequencing (NGS) technology has expanded in the last decades with enhancement in the reliability, sequencing chemistry, pipeline analyses, data interpretation and costs.  Such advances make the use of NGS feasible in clinical practice . This review describes the recent technological developments in NGS applied to the field of oncology.  Next-generation sequencing (NGS) is also called massive parallel sequencing  Some advantages of NGS sequencers are the high-throughput sequencing capacity of large genomic regions or small regions for many samples.  Nowadays, the use of NGS almost replaced conventional Sanger sequencing and is a very versatile approach for several clinical and non-clinical applications.  It is very cost effective
  • 4. AIM  The present review describes the major factor in NGS technology, the technical developments and application of NGS to the field of oncology, i.e., hereditary cancer syndromes and sporadic cancer and it’s diagnostics  NGS studies exploring the somatic mutation profile in cancer .  In clinical diagnostics, in order to identify familial germline mutations, WGS may be useful in case genetic tests based on WES returned a negative result in families with a high probability of carrying a genetic mutation.  A thorough overview of the different NGS platforms and approaches e.g. Illumina  Current NGS technology is sorted in two major types, i.e., short- and long-read sequencing  Short-read sequencing has low costs per Gb and high accuracy (low final error-rate; 0.1 Kb) and has been the method most frequently used .  In contrast, the low accuracy (high final error-rate; >1 Kb) and the high costs per Gb of long-read sequencing make the use of these approaches non-versatile for all- purposes
  • 5. PROCEDURE  The initial input material can be genomic DNA (DNA-seq), messenger or non-coding RNA (RNA-seq) or any nucleic/ribonucleic material obtained after specific procedures.  The implementation of NGS technology can be visualised as four major blocks:- 1) Library preparation 2) Sequencing 3) Quality analysis 4) Data Analysis interpretation
  • 7. DATA ANYLYSIS  After raw data are assessed for sufficient quality, data analyses and interpretation continues using different pipelines depending on the approach used (gene-panel, WES, WGS or targeted-RNA-seq)  It was indicated that genes besides BRCA1 and BRCA2 are mutated and confer a moderate to high cancer risk  Aloraifi and co-workers [1] sequenced 312 genes among 104 BRCAx subjects and found that 13 subjects carried a pathogenic variant, most frequently occurring in ATM, RAD50, PALB2, CHEK2 and TP53
  • 9. CONCLUSION  In conclusions, liquid biopsy analyses by NGS have been applied to several cancer types like hepatocellular carcinoma [278], gynaecological cancer [2], lung cancer [3,5], urinary tract cancer [271], paediatric oncology [6], gastrointestinal tumours [7] and other types, even through WES/WGS analyses [8,9]  The NGS approach for PGx can involve the analysis of the entire exome (WES) or the entire genome (WGS). WGS has the main advantage of encompassing also the non-coding regions, e.g., involved in regulation of transcription or affecting splicing, which is not present in WES data  NGS has brought unprecedented advances in understanding the biology of diseases, with important clinical implications .
  • 10. REFERENCE 1. Aloraifi F., McDevitt T., Martiniano R., McGreevy J., McLaughlin R., Egan C.M., Cody N., Meany M., Kenny E., Green A.J., et al. Detection of novel germline mutations for breast cancer in non-BRCA1/2families. FEBS J. 2015;282:3424–3437. doi: 10.1111/febs.13352. [PubMed] [Cross Ref] 2. Forshew T., Murtaza M., Parkinson C., Gale D., Tsui D.W., Kaper F., Dawson S.J., Piskorz A.M., Jimenez-Linan M., Bentley D., et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci. Transl. Med. 2012;4:136ra68. doi: 10.1126/scitranslmed.3003726. [PubMed] [Cross Ref] 3. Couraud S., Vaca-Paniagua F., Villar S., Oliver J., Schuster T., Blanche H., Girard N., Tredaniel J., Guilleminault L., Gervais R., et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never- smokers: A proof-of-concept study from BioCAST/IFCT-1002. Clin. Cancer Res. 2014;20:4613–4624. doi: 10.1158/1078-0432.CCR-13-3063. [PubMed][Cross Ref] 4. Ward D.G., Baxter L., Gordon N.S., Ott S., Savage R.S., Beggs A.D., James J.D., Lickiss J., Green S., Wallis Y., et al. Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer. PLoS ONE. 2016;11:e0149756 doi: 10.1371/journal.pone.0149756. [PMC free article][PubMed] [Cross Ref]
  • 11. 5. Xu S., Lou F., Wu Y., Sun D.Q., Zhang J.B., Chen W., Ye H., Liu J.H., Wei S., Zhao M.Y., et al. Circulating tumor DNA identified by targeted sequencing in advanced-stage non-small cell lung cancer patients. Cancer Lett. 2016;370:324–331. doi: 10.1016/j.canlet.2015.11.005. [PubMed] [Cross Ref] 6. Kurihara S., Ueda Y., Onitake Y., Sueda T., Ohta E., Morihara N., Hirano S., Irisuna F., Hiyama E. Circulating free DNA as non-invasive diagnostic biomarker for childhood solid tumors. J. Pediatr. Surg. 2015;50:2094–2097. doi: 10.1016/j.jpedsurg.2015.08.033. [PubMed] [Cross Ref] 7. Ueda M., Iguchi T., Masuda T., Nakahara Y., Hirata H., Uchi R., Niida A., Momose K., Sakimura S., Chiba K., et al. Somatic mutations in plasma cell-free DNA are diagnostic markers for esophageal squamous cell carcinoma recurrence. Oncotarget. 2016;7:62280– 62291. doi: 10.18632/oncotarget.11409.[PMC free article] [PubMed] [Cross Ref] 8. Gasch C., Pantel K., Riethdorf S. Whole Genome Amplification in Genomic Analysis of Single Circulating Tumor Cells. Methods Mol. Biol. 2015;1347:221–232. [PubMed] 9. Huang L., Ma F., Chapman A., Lu S., Xie X.S. Single-Cell Whole-Genome Amplification and Sequencing: Methodology and Applications. Annu. Rev. Genom. Hum. Genet. 2015;16:79– 102. doi: 10.1146/annurev-genom-090413-025352. [PubMed] [Cross Ref]